BOSP is a successful treatment option for severe periorbital thermal injuries

Article

Using the Boston Ocular Surface Prosthesis (BOSP) on patients with severe periorbtial thermal injuries is a rehabilitating and successful treatment option.

Using the Boston Ocular Surface Prosthesis (BOSP) on patients with severe periorbtial thermal injuries is a rehabilitating and successful treatment option, claims a paper published in Ophthalmology.

Dr Kevin Kalwerisky et al., San Antonio Uniformed Services Health Education Consortium, Texas, USA, conducted a retrospective, interventional case series on 16 eyes of 10 consecutive patients with periorbital thermal injuries. All patients had been treated with the Boston Ocular Surface Prosthesis (BOSP) prior to the investigation. This is an FDA-approved gas-permeable, scleral contact lens.

All patients obtained their injuries through combat mission in Iraq and Afghanistan and were treated for exposure to keratopathy and the BOSP. The main outcome measures included corneal epithelial defect healing, uncorrected visual acuity, best-corrected visual acuity and BOSP wear-time.

After chronic ocular exposure all patients developed vision-threatening ocular surface disease. BOSP enables the rehabilitation of the ocular surface. Of the 16 eyes studied, 10 presented with a corrected visual acuity of 20/70 or better and a best-corrected visual acuity of 20/40 or better was achieved in 5 eyes.

Corneal ulcers were safely and successfully treated in 6 eyes by using the BOSP as a drug delivery vehicle. Only one eye required penetrating keratoplasty, but this was due to direct sequelae of the initial thermal burn.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.